StockNews.AI
IGMS
StockNews.AI
215 days

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS

1. Pomerantz LLP is investigating possible securities fraud involving IGM. 2. IGM's stock dropped 66.29% after halting drug development. 3. Interim data from Phase 1b studies showed inadequate results. 4. Investigations often signal potential financial misconduct by companies. 5. Class action firms frequently see substantial settlements for investors.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The significant stock price drop indicates severe investor loss of confidence, similar to past scandal-driven declines.

How important is it?

The investigation and the recent stock drop are crucial events that could shape IGMS's future performance.

Why Short Term?

Immediate selling pressure due to ongoing investigations can impact stock price soon.

Related Companies

IGMS
Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether IGM and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class]On January 9, 2025, IGM issued a press release "announc[ing] a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases." The press release quoted Mary Beth Harler, M.D., the Company's Chief Executive Officer, as stating that "[i]nterim data from the Phase 1b studies of imvotamab in rheumatoid arthritis and systemic lupus erythematosus show that the depth and consistency of B cell depletion is insufficient to meet our high bar for success[.]"On this news, IGM's stock price fell $4.11 per share, or 66.29%, to close at $2.09 per share on January 10, 2025.Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.Attorney advertising. Prior results do not guarantee similar outcomes.SOURCE: Pomerantz LLP

Related News